An observational study in Stomach Neoplasms, Benign, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Chinese University of Hong Kong · Observational
This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.
2,851 studies on the registry are indexed under Stomach Neoplasms; 864 are open to participants now.
This study's planned enrollment of 100 is below the median of 274 across 670 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients admitted into PWH
Exclusion Criteria:
Biobank construction
Recruit patients and collect the required biological samples (i.e. tumor tissues, blood and ascites samples) for biobank construction.
Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Detection of noval therapeutic targets for treating gastric cancer cancer with metastases.
Biological samples (i.e. tissue, blood and ascites samples) collected from enrolled patients will be used in genome and transcriptome analysis using next generation sequencing, DNA mutation detection using digital PCR and mass spectrometry-based proteomic.
Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Organoid culture for drug sensitivity assay
Gastric tumor tissues are collected from enrolled patients to establish patient-derived organoids and subject to drug sensitivity assay. The choice of drugs will depend on the molecular analysis results and will be advised by oncologists.
Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Clinical Outcome - Overall survival
Patients' overall survival will also be recorded.
Time frame: through study completion, an average of 5 year
Clinical Outcome - Progression-free survival
Patients' progression-free survival will also be recorded.
Time frame: through study completion, an average of 5 year
Clinical Outcome - Karnofsky Score
Karnofsky Score for measuring quality of life will be recorded
Time frame: At baseline measurement
Clinical Outcome - Time point of metastasis
Patients' time point of metastasis, whether it is synchronous or metachronous will be recorded
Time frame: Recruitment till death or 5 year
Clinical Outcome - Number of previous chemotherapy/ target therapy/ immunotherapy
Number of previous chemotherapy/ target therapy/ immunotherapy received by the patients will be recorded
Time frame: Measured and asked at baseline
Clinical Outcome - Presence of ascites
Presence of ascites on recruited patients will be recorded
Time frame: Recruitment till death or 5 year
Clinical Outcome - Cancer Restaging
Stage of cancer will be recorded and determined with CT/PETCT scan
Time frame: Post-treatment till death or 5 year
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong